LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 28

Search options

  1. Article ; Online: Latest animal models for anti-HIV drug discovery.

    Sliva, Katja

    Expert opinion on drug discovery

    2015  Volume 10, Issue 2, Page(s) 111–123

    Abstract: Introduction: HIV research is limited by the fact that lentiviruses are highly species specific. The need for appropriate models to promote research has led to the development of many elaborate surrogate animal models.: Areas covered: This review ... ...

    Abstract Introduction: HIV research is limited by the fact that lentiviruses are highly species specific. The need for appropriate models to promote research has led to the development of many elaborate surrogate animal models.
    Areas covered: This review looks at the history of animal models for HIV research. Although natural animal lentivirus infections and chimeric viruses such as chimera between HIV and simian immunodeficiency virus and simian-tropic HIV are briefly discussed, the main focus is on small animal models, including the complex design of the 'humanized' mouse. The review also traces the historic evolution and milestones as well as depicting current models and future prospects for HIV research.
    Expert opinion: HIV research is a complex and challenging task that is highly manpower-, money- and time-consuming. Besides factors such as hypervariability and latency, the lack of appropriate animal models that exhibit and recapitulate the entire infectious process of HIV, is one of the reasons behind the failure to eliminate the lentivirus from the human population. This obstacle has led to the exploitation and further development of many sophisticated surrogate animal models for HIV research. While there is no animal model that perfectly mirrors and mimics HIV infections in humans, there are a variety of host species and viruses that complement each other. Combining the insights from each model, and critically comparing the results obtained with data from human clinical trials should help expand our understanding of HIV pathogenesis and drive future drug development.
    MeSH term(s) Animals ; Anti-HIV Agents ; Disease Models, Animal ; Drug Discovery/methods ; Drug Discovery/trends ; HIV Infections/drug therapy ; HIV Infections/virology ; Humans ; Species Specificity
    Chemical Substances Anti-HIV Agents
    Language English
    Publishing date 2015-02
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 2259618-5
    ISSN 1746-045X ; 1746-0441
    ISSN (online) 1746-045X
    ISSN 1746-0441
    DOI 10.1517/17460441.2015.975201
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Allergen-specific immunotherapy and evidence: A European regulatory perspective.

    Bartel, Detlef / Bonertz, Andreas / Hartenstein, Diana / Kaul, Stefan / Lauer, Iris / Reeb, Christina / Rösner-Friese, Karen / Sliva, Katja / Zimmer, Julia / Vieths, Stefan / Mahler, Vera

    Allergologie select

    2023  Volume 7, Page(s) 198–210

    Abstract: Allergen immunotherapy (AIT) has been performed for 112 years. In this article we summarize regulatory standards and challenges based on scientific evidence on AIT. Most crucial and timely aspects concerning AIT are addressed from the regulatory ... ...

    Abstract Allergen immunotherapy (AIT) has been performed for 112 years. In this article we summarize regulatory standards and challenges based on scientific evidence on AIT. Most crucial and timely aspects concerning AIT are addressed from the regulatory perspective of the authors as employees of a national competent authority in Europe: (1) product specificity; (2) clinical efficacy; (3) treatment for adults and children (needs for extrapolation); (4) allergen exposure chambers; (5) biomarkers; (6) standardization; (7) real-world evidence; (8) independent official batch release (benefit and challenges); (9) harmonization on the EU level. The Paul-Ehrlich-Institut (PEI), the Federal Institute for Vaccines and Biomedicines, in Langen near Frankfurt/Main in Germany, examines and evaluates the benefits and risks of AIT products within the course of clinical development, marketing authorization, and subsequently throughout their entire life cycle to ensure high-quality, safe, and effective AIT products.
    Language English
    Publishing date 2023-12-12
    Publishing country Germany
    Document type Journal Article ; Review
    ZDB-ID 2893503-2
    ISSN 2512-8957 ; 2512-8957
    ISSN (online) 2512-8957
    ISSN 2512-8957
    DOI 10.5414/ALX02413E
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Book ; Online ; Thesis: Charakterisierung und Optimierung von replikationskompetenten murinen Leukämieviren (MLV) als Gentransfervehikel

    Sliva, Katja

    2006  

    Author's details von Katja Sliva
    Language German
    Size Online-Ressource
    Document type Book ; Online ; Thesis
    Thesis / German Habilitation thesis Univ., Diss--Frankfurt (Main), 2006
    Database Former special subject collection: coastal and deep sea fishing

    More links

    Kategorien

  4. Article ; Online: Selective gene silencing by viral delivery of short hairpin RNA.

    Sliva, Katja / Schnierle, Barbara S

    Virology journal

    2010  Volume 7, Page(s) 248

    Abstract: RNA interference (RNAi) technology has not only become a powerful tool for functional genomics, but also allows rapid drug target discovery and in vitro validation of these targets in cell culture. Furthermore, RNAi represents a promising novel ... ...

    Abstract RNA interference (RNAi) technology has not only become a powerful tool for functional genomics, but also allows rapid drug target discovery and in vitro validation of these targets in cell culture. Furthermore, RNAi represents a promising novel therapeutic option for treating human diseases, in particular cancer. Selective gene silencing by RNAi can be achieved essentially by two nucleic acid based methods: i) cytoplasmic delivery of short double-stranded (ds) interfering RNA oligonucleotides (siRNA), where the gene silencing effect is only transient in nature, and possibly not suitable for all applications; or ii) nuclear delivery of gene expression cassettes that express short hairpin RNA (shRNA), which are processed like endogenous interfering RNA and lead to stable gene down-regulation. Both processes involve the use of nucleic acid based drugs, which are highly charged and do not cross cell membranes by free diffusion. Therefore, in vivo delivery of RNAi therapeutics must use technology that enables the RNAi therapeutic to traverse biological membrane barriers in vivo. Viruses and the vectors derived from them carry out precisely this task and have become a major delivery system for shRNA. Here, we summarize and compare different currently used viral delivery systems, give examples of in vivo applications, and indicate trends for new developments, such as replicating viruses for shRNA delivery to cancer cells.
    MeSH term(s) Gene Knockdown Techniques/methods ; Genetic Vectors ; Humans ; RNA, Small Interfering/genetics ; RNA, Small Interfering/metabolism ; Transduction, Genetic ; Viruses/genetics
    Chemical Substances RNA, Small Interfering
    Keywords covid19
    Language English
    Publishing date 2010-09-21
    Publishing country England
    Document type Journal Article ; Review
    ISSN 1743-422X
    ISSN (online) 1743-422X
    DOI 10.1186/1743-422X-7-248
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Interference with SAMHD1 Restores Late Gene Expression of Modified Vaccinia Virus Ankara in Human Dendritic Cells and Abrogates Type I Interferon Expression.

    Sliva, Katja / Martin, Judith / von Rhein, Christine / Herrmann, Tobias / Weyrich, Anastasia / Toda, Masako / Schnierle, Barbara S

    Journal of virology

    2019  Volume 93, Issue 22

    Abstract: Attenuated poxviruses like modified vaccinia virus Ankara (MVA) are promising vectors for vaccines against infectious diseases and cancer. However, host innate immune responses interfere with the viral life cycle and also influence the immunogenicity of ... ...

    Abstract Attenuated poxviruses like modified vaccinia virus Ankara (MVA) are promising vectors for vaccines against infectious diseases and cancer. However, host innate immune responses interfere with the viral life cycle and also influence the immunogenicity of vaccine vectors. Sterile alpha motif (SAM) domain and histidine-aspartate (HD) domain-containing protein 1 (SAMHD1) is a phosphohydrolase and reduces cellular deoxynucleoside triphosphate (dNTP) concentrations, which impairs poxviral DNA replication in human dendritic cells (DCs). Human immunodeficiency virus type 2 (HIV-2) and simian immunodeficiency virus (SIV) encode an accessory protein called viral protein X (Vpx) that promotes proteasomal degradation of SAMHD1, leading to a rapid increase in cellular dNTP concentrations. To study the function of SAMHD1 during MVA infection of human DCs, the SIV
    MeSH term(s) A549 Cells ; Animals ; Cell Line ; Dendritic Cells/metabolism ; Dendritic Cells/virology ; Gene Expression Regulation, Viral ; HEK293 Cells ; HeLa Cells ; Host-Pathogen Interactions ; Humans ; Interferon Type I/genetics ; Interferon Type I/metabolism ; Monomeric GTP-Binding Proteins/metabolism ; Proteolysis ; SAM Domain and HD Domain-Containing Protein 1/genetics ; SAM Domain and HD Domain-Containing Protein 1/metabolism ; Simian Immunodeficiency Virus/physiology ; Vaccinia virus/genetics ; Vaccinia virus/metabolism ; Viral Regulatory and Accessory Proteins/metabolism ; Virus Replication/physiology
    Chemical Substances Interferon Type I ; VPX protein, Simian immunodeficiency virus ; Viral Regulatory and Accessory Proteins ; SAM Domain and HD Domain-Containing Protein 1 (EC 3.1.5.-) ; SAMHD1 protein, human (EC 3.1.5.-) ; Monomeric GTP-Binding Proteins (EC 3.6.5.2)
    Language English
    Publishing date 2019-10-29
    Publishing country United States
    Document type Journal Article
    ZDB-ID 80174-4
    ISSN 1098-5514 ; 0022-538X
    ISSN (online) 1098-5514
    ISSN 0022-538X
    DOI 10.1128/JVI.01097-19
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Book ; Online ; Thesis: Charakterisierung und Optimierung von replikationskompetenten murinen Leukämieviren (MLV) als Gentransfervehikel

    Sliva, Katja [Verfasser]

    2006  

    Author's details von Katja Sliva
    Keywords Medizin, Gesundheit ; Medicine, Health
    Subject code sg610
    Document type Book ; Online ; Thesis
    Database Digital theses on the web

    More links

    Kategorien

  7. Article: Selective gene silencing by viral delivery of short hairpin RNA

    Sliva, Katja / Schnierle, Barbara S

    Virology journal. 2010 Dec., v. 7, no. 1

    2010  

    Abstract: RNA interference (RNAi) technology has not only become a powerful tool for functional genomics, but also allows rapid drug target discovery and in vitro validation of these targets in cell culture. Furthermore, RNAi represents a promising novel ... ...

    Abstract RNA interference (RNAi) technology has not only become a powerful tool for functional genomics, but also allows rapid drug target discovery and in vitro validation of these targets in cell culture. Furthermore, RNAi represents a promising novel therapeutic option for treating human diseases, in particular cancer. Selective gene silencing by RNAi can be achieved essentially by two nucleic acid based methods: i) cytoplasmic delivery of short double-stranded (ds) interfering RNA oligonucleotides (siRNA), where the gene silencing effect is only transient in nature, and possibly not suitable for all applications; or ii) nuclear delivery of gene expression cassettes that express short hairpin RNA (shRNA), which are processed like endogenous interfering RNA and lead to stable gene down-regulation. Both processes involve the use of nucleic acid based drugs, which are highly charged and do not cross cell membranes by free diffusion. Therefore, in vivo delivery of RNAi therapeutics must use technology that enables the RNAi therapeutic to traverse biological membrane barriers in vivo. Viruses and the vectors derived from them carry out precisely this task and have become a major delivery system for shRNA. Here, we summarize and compare different currently used viral delivery systems, give examples of in vivo applications, and indicate trends for new developments, such as replicating viruses for shRNA delivery to cancer cells.
    Keywords RNA interference ; cell culture ; drugs ; gene expression ; genes ; genomics ; humans ; oligonucleotides ; small interfering RNA ; therapeutics ; virology
    Language English
    Dates of publication 2010-12
    Size p. 248.
    Publishing place BioMed Central
    Document type Article
    Note Review
    ZDB-ID 2160640-7
    ISSN 1743-422X
    ISSN 1743-422X
    DOI 10.1186/1743-422X-7-248
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

  8. Article ; Online: Vaccination directed against the human endogenous retrovirus-K (HERV-K) gag protein slows HERV-K gag expressing cell growth in a murine model system.

    Kraus, Benjamin / Fischer, Katrin / Sliva, Katja / Schnierle, Barbara S

    Virology journal

    2014  Volume 11, Page(s) 58

    Abstract: Background: Human endogenous retroviruses (HERVs) are remnants of ancestral infections and chromosomally integrated in all cells of an individual, are transmitted only vertically and are defective in viral replication. However enhanced expression of ... ...

    Abstract Background: Human endogenous retroviruses (HERVs) are remnants of ancestral infections and chromosomally integrated in all cells of an individual, are transmitted only vertically and are defective in viral replication. However enhanced expression of HERV-K accompanied by the emergence of anti-HERV-K-directed immune responses has been observed inter-alia in HIV-infected individuals and tumor patients. Therefore HERV-K might serve as a tumor-specific antigen or even as a constant target for the development of an HIV vaccine.
    Results: To verify our hypothesis, we tested the immunogenicity of HERV-K Gag by using a recombinant vaccinia virus (MVA-HKcon) expressing the HERV-K Gag protein and established an animal model to test its vaccination efficacy. Murine renal carcinoma cells (Renca) were genetically altered to express E. coli beta-galactosidase (RLZ cells) and the HERV-K Gag protein (RLZ-HKGag cells). Subcutaneous application of RLZ-HKGag cells into syngenic BALB/c mice resulted in the formation of local tumors in MVA vaccinated mice. MVA-HKcon vaccination reduced the tumor growth. Furthermore, intravenous injection of RLZ-HKGag cells led to the formation of pulmonary metastases. Vaccination of tumor-bearing mice with MVA-HKcon drastically reduced the number of pulmonary RLZ-HKGag tumor nodules compared to vaccination with wild-type MVA.
    Conclusion: The data demonstrate that HERV-K Gag is a useful target for vaccine development and might offer new treatment opportunities for cancer patients.
    MeSH term(s) Animals ; Cancer Vaccines/administration & dosage ; Cancer Vaccines/immunology ; Cell Proliferation ; Endogenous Retroviruses/immunology ; Female ; Gene Products, gag/immunology ; Mice ; Neoplasms/immunology ; Vaccination/methods ; Viral Vaccines/administration & dosage ; Viral Vaccines/immunology
    Chemical Substances Cancer Vaccines ; Gene Products, gag ; Viral Vaccines
    Language English
    Publishing date 2014-03-26
    Publishing country England
    Document type Journal Article
    ISSN 1743-422X
    ISSN (online) 1743-422X
    DOI 10.1186/1743-422X-11-58
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Selective gene silencing by viral delivery of short hairpin RNA

    Sliva Katja / Schnierle Barbara S

    Virology Journal, Vol 7, Iss 1, p

    2010  Volume 248

    Abstract: Abstract RNA interference (RNAi) technology has not only become a powerful tool for functional genomics, but also allows rapid drug target discovery and in vitro validation of these targets in cell culture. Furthermore, RNAi represents a promising novel ... ...

    Abstract Abstract RNA interference (RNAi) technology has not only become a powerful tool for functional genomics, but also allows rapid drug target discovery and in vitro validation of these targets in cell culture. Furthermore, RNAi represents a promising novel therapeutic option for treating human diseases, in particular cancer. Selective gene silencing by RNAi can be achieved essentially by two nucleic acid based methods: i) cytoplasmic delivery of short double-stranded (ds) interfering RNA oligonucleotides (siRNA), where the gene silencing effect is only transient in nature, and possibly not suitable for all applications; or ii) nuclear delivery of gene expression cassettes that express short hairpin RNA (shRNA), which are processed like endogenous interfering RNA and lead to stable gene down-regulation. Both processes involve the use of nucleic acid based drugs, which are highly charged and do not cross cell membranes by free diffusion. Therefore, in vivo delivery of RNAi therapeutics must use technology that enables the RNAi therapeutic to traverse biological membrane barriers in vivo . Viruses and the vectors derived from them carry out precisely this task and have become a major delivery system for shRNA. Here, we summarize and compare different currently used viral delivery systems, give examples of in vivo applications, and indicate trends for new developments, such as replicating viruses for shRNA delivery to cancer cells.
    Keywords Microbiology ; QR1-502 ; Science ; Q ; DOAJ:Microbiology ; DOAJ:Biology ; DOAJ:Biology and Life Sciences ; Medicine (General) ; R5-920 ; Medicine ; R ; DOAJ:Medicine (General) ; DOAJ:Health Sciences
    Subject code 500
    Language English
    Publishing date 2010-09-01T00:00:00Z
    Publisher BioMed Central
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  10. Article ; Online: From actually toxic to highly specific--novel drugs against poxviruses.

    Sliva, Katja / Schnierle, Barbara

    Virology journal

    2007  Volume 4, Page(s) 8

    Abstract: The potential use of variola virus, the causative agent of smallpox, as a bioweapon and the endemic presence of monkeypox virus in Africa demonstrate the need for better therapies for orthopoxvirus infections. Chemotherapeutic approaches to control viral ...

    Abstract The potential use of variola virus, the causative agent of smallpox, as a bioweapon and the endemic presence of monkeypox virus in Africa demonstrate the need for better therapies for orthopoxvirus infections. Chemotherapeutic approaches to control viral infections have been less successful than those targeting bacterial infections. While bacteria commonly reproduce themselves outside of cells and have metabolic functions against which antibiotics can be directed, viruses replicate in the host cells using the cells' metabolic pathways. This makes it very difficult to selectively target the virus without damaging the host. Therefore, the development of antiviral drugs against poxviruses has initially focused on unique properties of the viral replication cycle or of viral proteins that can be selectively targeted. However, recent advances in molecular biology have provided insights into host factors that represent novel drug targets. The latest anti-poxvirus drugs are kinase inhibitors, which were originally developed to treat cancer progression but in addition block egress of poxviruses from infected cells. This review will summarize the current understanding of anti-poxvirus drugs and will give an overview of the development of the latest second generation poxvirus drugs.
    MeSH term(s) Animals ; Antiviral Agents/pharmacology ; Antiviral Agents/therapeutic use ; Enzyme Inhibitors/pharmacology ; Enzyme Inhibitors/therapeutic use ; Humans ; Mice ; Orthopoxvirus/classification ; Orthopoxvirus/drug effects ; Orthopoxvirus/enzymology ; Orthopoxvirus/physiology ; Phosphotransferases/antagonists & inhibitors ; Poxviridae Infections/drug therapy ; Poxviridae Infections/virology ; Viral Proteins/drug effects ; Viral Proteins/metabolism ; Virus Replication/drug effects
    Chemical Substances Antiviral Agents ; Enzyme Inhibitors ; Viral Proteins ; Phosphotransferases (EC 2.7.-)
    Language English
    Publishing date 2007-01-15
    Publishing country England
    Document type Journal Article ; Review
    ISSN 1743-422X
    ISSN (online) 1743-422X
    DOI 10.1186/1743-422X-4-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top